Mortality prospects after a prostate cancer recurrences following a radical prostatectomy has always been assumed to be directly related to the early development of metastases. A study from Melbourne Australia indicates that men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence. The first author of the study, Anthony [...]
There has been much discussion about the timing of treatments now that we have new drugs available to treat advanced prostate cancer. However, today’s technology does not allow us to know what the best sequencing of these drugs to maximize their efficacy would be, so we just punt along. We do not know whether or [...]
It is unfortunate, but some of us will approach a time when we know that the advanced prostate cancer we have been battling has gotten the better of us and will end our life in the near future. If we are admitted into the hospital we will be asked to sign a lot of papers [...]
Some mornings we just wake up to great news and today is one of those mornings. The Food and Drug Administration (FDA) has just announced that they have approved Zytiga (abiraterone acetate) for use prior to chemotherapy. - This FDA announcement is an expansion of their prior approved (April 2011) for the use of Zytiga [...]
We all know that LHRH agonists are used for androgen deprivation therapy (ADT) cause a tremendous number of side effects, but it is not uncommon for our doctors to never discuss these potential side effects with us prior to starting therapy. Additionally, doctors neglect to offer alternative therapies that might accomplish the same results (like [...]